Treatment options for deep vein thrombosis

Bibliography

• Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960;1:1309-12
   PubMed Web of Science ®Google Scholar
• Kearon C, Kahn SR, Agnelli G, Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines. 8th edition. Chest 2008;133(6 Suppl):454S-545S
   Web of Science ®Google Scholar
• Imberti D, Dall'Asta C, Pierfranceschi MG. Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Intern Emerg Med 2009;4:471-78
   PubMed Web of Science ®Google Scholar
• Squizzato A, Dentali F, Steidl L, Ageno W. New direct thrombin inhibitors. Intern Emerg Med 2009;4:479-84
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C. New oral anticoagulants: just a new therapeutic option or a real breakthrough? Intern Emerg Med 2009;4:455-58
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40
   PubMed Web of Science ®Google Scholar
• Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines. 8th edition. Chest 2008;133:234-56
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors development. Clin Pharmacokinet 2009;48:1-22
   PubMed Web of Science ®Google Scholar
• Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003;109(Suppl 1):S9-S15
   Google Scholar
• Mungall D. BIBR-1048 Boehringer Ingelheim. Curr Opin Invest Drugs 2002;3:905-7
   PubMedGoogle Scholar
• Stangier J, Rathgen K, Stahle H, The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303
   PubMed Web of Science ®Google Scholar
• Wienen W, Stassen JM, Priepke H, Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost 2007;98:333-8
   PubMed Web of Science ®Google Scholar
• Lip GY, Rasmussen LH, Olsson SB, Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009;30:2897-907
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). European public assessment report: Pradaxa [online]. Available from: http://www.emea.europa.eu
   Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 2007;370:949-56
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Davidson BL, Comp PC, The oral thrombin inhibitor dabigatran etexilate vs the north american enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;2:1-9
   Google Scholar
• Wolowacz SE, Roskell NS, Plumb JM, Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009;101:77-85
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ [Last accessed on 12 January 2010]
   Google Scholar
• Schulman S, Kearon C, Kakkar AK, Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Reilly PA, Nehmiz G, Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007;100:1419-26
   PubMed Web of Science ®Google Scholar
• Fiessinger JN, Huisman MV, Davidson BL, Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293:681-9
   PubMed Web of Science ®Google Scholar
• Bauer KA. New anticoagulants: anti IIa vs anti Xa—is one better? J Thromb Thrombolysis 2006;21:67-72
   PubMed Web of Science ®Google Scholar
• Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007;27:1238-47
   PubMed Web of Science ®Google Scholar
• Pinto DJ, Orwat MJ, Koch S, Discovery of 1-(4-methoxyphenyl)7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007;50:5339-556
   PubMed Web of Science ®Google Scholar
• Wong PC, Crain EJ, Xin B, Apixaban, an oral, direct and selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2007;6:820-9
   Web of Science ®Google Scholar
• Strassburger J, Wilmen A, Pohlmann J, In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939—an oral, direct factor Xa inhibitor. J Thromb Haemost 2005;3:514-21
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M, Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006;46:549-58
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). European public assessment report: Xarelto [online]. Available from: http://www.emea.europa.eu
   Google Scholar
• Gruber A, Marzec UM, Buetehorn U, Recombinant factor VIIa reverses the effects of a high dose of rivaroxaban in baboons. Pathophysiol Haemost Thromb 2007;36(Suppl 1): abstract A39
   Google Scholar
• Perzborn E, Tinel H. FEIBA reverses the effects of a high dose of rivaroxaban in rats. Pathophysiol Haemost Thromb 2007;36(Suppl 1):, abstract A40
   Google Scholar
• Lassen MR, Raskob GE, Gallus A, Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604
   PubMed Web of Science ®Google Scholar
• Lassen MR, Gallus AS, Pineo GF, Raskob GE. The ADVANCE–2 study: a randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement. J Thromb Haemost 2009;7(2): abstract LB-MO-005
   Google Scholar
• Eriksson BI, Borris LC, Friedman RJ, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE, Extended duration rivaroxaban versus short term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Davidson BL, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-80
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Kakkar AK, Turpie AG, Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009;91:636-44
   PubMed Web of Science ®Google Scholar
• Buller HR, Einstein investigators. Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism. The Einstein-Extension Study. Blood 2009;114:LBA2
   Google Scholar
• Van Thiel D, Kalodiki E, Wahi R, Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. Clin Appl Thromb Hemost 2009;15:389-94
   PubMed Web of Science ®Google Scholar